Efficacy and safety of total lymphoid irradiation in different chronic lung allograft dysfunction phenotypes.

Total lymphoid irradiation (TLI) is an alternative treatment for chronic lung allograft dysfunction (CLAD). However, data regarding its efficacy and tolerance are scarce. This study included patients with CLAD treated with TLI at our center between 2011 and 2018. Clinical characteristics before and after TLI and related complications were analyzed. Forty patients with CLAD (twenty-nine bronchiolitis obliterans syndrome [BOS], nine restrictive allograft syndrome [RAS], and two mixed) were included. Significant attenuation of the forced expiratory volume in 1-sec (FEV1 ) decline slope was observed in all phenotypes, in both the BOS and RAS. The median FEV1 12, 6, and 3 months pre-TLI were as follows: 1980 (IQR 1720-2560), 1665 (IQR 1300-2340) and 1300 (IQR 1040-1740) ml (p < .001), while the median FEV1 at 3, 6, and 12 months post-TLI was 1110 (IQR 810-1440), 1130 (IQR 860-1470), and 1115 (IQR 865-1490) ml (p = .769). No dropouts due to radiation toxicity were observed. The mean survival according to the Karnofsky Performance Status Scale (KPS) >70 or ≤70 at baseline was 1837 (IQR 259-2522) versus 298 (IQR 128-554) days (p < .0001), respectively. In conclusion, TLI may stop FEV1 decline in both BOS and RAS. Moreover, a good KPS score may be an important prognostic factor.

Stereotactic ablative radiotherapy (SABR) for patients with lung tumor and severe pulmonary function impairment.

PURPOSE: To evaluate clinical outcomes after SABR in a cohort of early-stage non-small cell lung cancer (NSCLC) or pulmonary metastases in chronic obstructive pulmonary disease (COPD) patients with forced expiratory volume in the first second predicted (FEV1) ≤ 50%. METHODS: Retrospective single-center study was performed to analyze clinical outcomes and toxicities in COPD patients with severe lung dysfunction treated with SABR from 1st June 2015 to 31st October 2022. RESULTS: Thirty four patients (forty locations) were enrolled for analysis. Median follow-up was 2.9 years. Median age was 73.5 years (range, 65.6-80.1). FEV1 was 38% (range, 28.2-50.0) prior to radiotherapy. Median overall survival (OS) was 41.1 months (95% CI 38.9-not reached). OS rates at 2-, 3-, and 5- years were 79%, 71%, and 36%, respectively. Cancer-specific survival rates at 2-, 3-, and 5- years were 96%, 96%, and 68%, respectively. Local control rates at 2-, 3-, and 5- years were 88%, 83%, and 83%, respectively. No grade 4 or 5 toxicity was observed. The most common acute toxicity was pneumonitis (38.2%), of which only 1 patient (2.9%) reported grade 3 acute toxicity. CONCLUSIONS: Lung SABR in patients with poor pulmonary function may be effective with acceptable toxicity.

Localización y clínica asociada al cáncer de colon: Hospital Nacional Arzobispo Loayza: 2009 - 2013 / Location and associated clinical characteristics of colon cancer: Hospital Nacional Arzobispo Loayza: 2009 - 2013

OBJETIVO: Determinar la clínica asociada a la localización del cáncer de colon en pacientes del Hospital Nacional Arzobispo Loayza durante el periodo mayo 2009 - setiembre 2013. MATERIAL Y MÉTODOS: estudio transversal que analizó información de 114 pacientes con neoplasia maligna primaria de colon, de los cuales 42 cumplieron los criterios de inclusión; internados en el Servicio 6-II del Departamento de Cirugía General del Hospital Nacional Arzobispo Loayza entre mayo 2009 y setiembre 2013. RESULTADOS: La media de edad fue de 60.5 años, y predominó el género femenino con 66.7%. El 100% de los tipos histológicos fue adenocarcinoma. El colon derecho resultó afectado en 61.9%, el izquierdo en 33,3% y un 4,8% presentó localización mixta. En la topografía, se halló 33,3% en colon ascendente y 21,4% en colon sigmoides. Los síntomas más frecuentes fueron dolor abdominal (76,2%), pérdida de peso (69%) y anemia (64%). Para el colon derecho, hubo 13 veces más riesgo de presentar astenia, y 4.44 veces más riesgo de presentar anemia (p<0,05). CONCLUSIÓN: La localización de cáncer de colon más frecuente fue en el colon derecho, el cual se asoció significativamente a la presencia de astenia y anemia en el cuadro clínico. Los síntomas más presentados fueron el dolor abdominal y la pérdida de peso, en cualquiera de sus localizaciones. Todos los casos fueron de adenocarcinoma. (Horiz Med 2015; 15(2): 49-55)

OBJECTIVE: To determine the association between the clinical characteristics and the location of colon cancer in patients hospitalized at "Hospital Nacional Arzobispo Loayza", during May 2009 - September 2013. MATERIAL AND METHODS: transversal study of 144 patients with primary colon cancer, of which 42 patients met the inclusion criteria; hospitalized in the 6-II Wing of the Department of General Surgery at "Hospital Nacional Arzobispo Loayza", between May 2009 and September 2013. RESULTS: the mean age was 60.5 years, and 66.7% of the cases were women. 100% of histologic types were adenocarcinoma. The right colon was affected in 61.9% of the cases; the left colon in 33.3%, and a mixed location in 4,8%. Regarding the topography, 33,3% of the cases were found in the ascending colon and 21,4% in the sigmoid colon. The most frequent symptoms were abdominal pain (76.2%), weight loss (69%) and anemia (64%). For right colon cancer, fatigue was 13 times more likely to appear, and anemia was 4.44 times more likely (p< 0.05). CONCLUSION: the most common location for cancer was in the right colon, and it was associated significantly with the presence of fatigue and anemia among the clinical characteristics. The most frequent symptoms were abdominal pain and weight loss, in any location. All cases were adenocarcinoma. (Horiz Med 2015; 15(2): 49-55)